BSX

Boston Scientific Corp. (BSX) | Rumor.io

Boston Scientific

BSX

Attention (50-day avg)0.04%

Attention rank (50-day avg)#203

Bullish sentiment (50-day avg)83%

Price to earnings ratio17.8

Market capitalization63.9B

Earnings per share2.47

Dividend yield (TTM)—

Revenue (annual)20.1B

Net income (annual)2.9B

Social

What share of all stock conversation is about BSX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.03% -0.02	0.02% -0.01	0.05% +0.03	0.01% +0

Sep 29

Boston Scientific / Med Tech has seen guidance cuts that may have contributed to an interesting chart, potentially leading to a secular health technology backwind in the 2050s.
Congressman Kevin Hern has sold up to $6.3 million in stocks, including $BSX, with his sales dwarfing his purchases, including Apple.
A large premium of $2.1 million has been paid for the $BSX 40C Jan 21 option contract, indicating potential large-scale trading activity.

Generated by AI

Sentiment

Of the messages about BSX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	94.34% +66.21	84.85% +21.12	65.85% -27.84	58.13% -37.32
Bearish	5.66% -66.21	15.15% -21.12	34.15% +27.84	41.87% +37.32

Bullish· Sep 10

Boston Scientific's management is actively buying the stock, with Chairman and CEO Michael Mahoney making an enormous open-market purchase of 186,240 shares at an average price of approximately $48.33.
The stock's fair value is likely to be $55-$65, and it may reach this price around April 2027 at the current rate.
Despite concerns about the cybersecurity disruption and slower growth expectations, the stock is undervalued and presents a unique opportunity, with many insiders and experts remaining bullish on its future prospects.

Bearish· Sep 10

The CEO's buy during the cyberattack was seen as poor timing, and the company's momentum was severely impacted.
The stock has been unable to recover from its losses, with the majority of posts indicating a trend of new lows and a lack of turnaround in sight.
The company's fundamental value has been questioned, with one post suggesting that buying fundamentally cheap stocks has been a disaster, and another recommending selling November 20 puts to collect a premium.

Generated by AI

Topics

Of the messages about BSX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	75%	86.05%	1.08%	4.98%
Technical Analysis	25%	13.18%	2.06%	4.77%
Analysts	0%	0%	50.36%	47.19%
Macro	0%	0%	46.42%	38.84%
Controversies	0%	0.78%	0.06%	2.15%
Earnings	0%	0%	0.03%	2.07%

Earnings· Feb 4

Boston Scientific's Q4 2025 earnings reported adjusted EPS of $0.80, beating estimates of $0.78.
Revenue for Q4 2025 was $5.29B, exceeding estimates of $5.28B and marking a 15.9% year-over-year growth.
The company guided Q1 2026 EPS to be between $0.78 and $0.80, and FY26 adjusted EPS to be between $3.43 and $3.49.

Analysts· Jan 1

Boston Scientific Corporation (BSX) is included in J.P Morgan's top stock picks for 2026 with an "overweight" rating and a price target of $135.00.
The analysts at J.P Morgan have expressed optimism about the company's prospects, although specific details of their reasoning are not provided.
The inclusion of BSX in J.P Morgan's top stock picks is seen as a positive development for the company's stock price.

Announcements· Aug 26

Boston Scientific ($BSX) disclosed a cybersecurity incident that disrupted global operations, including systems used to process and ship customer orders.
The incident, detected on August 25, has caused a network outage and prevented the company from processing and shipping customer orders worldwide.
The company has not concluded whether the incident rises to a reportable level, and the financial impact and restoration timeline are unknown.

Technical Analysis· Jun 2

$BSX is down to test 2004 highs and may be due for a bounce.
The weekly chart shows $BSX has arrived at its trend curve, indicating a potential bounce starting soon.
A bullish divergence on the daily chart for CCI and volume against declining share prices suggests a reversal action may be inbound.

Generated by AI

Community

Of the messages about BSX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	3.86%	32.09%	65.27%	42.33%
Newcomers	96.14%	67.91%	34.73%	57.67%

Regulars· Sep 25

The management team is under scrutiny for the stock's performance, with some users calling for a change in leadership and others expressing frustration with the current team's competence.
The stock's price has been stagnant, with some users pointing to a "dirty fucking short ladder pattern" and others referencing a "short ladder" in a negative light, suggesting a lack of upward momentum.
Some users are holding onto hope for a "desperate pump" or a "buy the dip" opportunity, while others have given up and are looking to exit their positions, with one user stating they'll come back in at $38.

Newcomers· Sep 25

Newcomers to $BSX are focusing on the company's potential opportunities in healthcare, with some expressing high conviction in its stock.
Some users are analyzing the company's recent performance, including CEO purchases and buybacks, and are concerned about its support levels and potential for losses.
Others are questioning the stock's volatility, with one user stating that it can easily wipe out all its gains in a single day, and another expressing frustration with retail investors' impatience and lack of understanding of the market.

Generated by AI

Wells Fargo has put a number on the damage Boston Scientific Corporation’s (NYSE:BSX) August cybersecurity incident could do to its third-quarter results, which comes up to roughly $300 million in sales and about $0.13 per share in earnings. Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Boston Scientific to $48 from $50 […]

1d agoYahoo Finance

Why Oppenheimer Cut Boston Scientific’s Price Target by $20 Despite Keeping its Outperform Rating

Oppenheimer has become considerably more cautious on Boston Scientific Corporation (NYSE:BSX), but not cautious enough to abandon its bullish rating. Analyst Suraj Kalia lowered the firm’s price target on Boston Scientific to $65 from $85 on September 21, ahead of the company’s quarterly results, while maintaining an Outperform rating. Kalia is also reducing Oppenheimer’s fiscal […]

1d agoYahoo Finance

FDA Flags Boston Scientific Catheter Recall - Boston Scientific (NYSE:BSX)

Boston Scientific recalls Imager II Angiographic Catheters over tip detachment defect. Learn about patient risks & FDA safety updates.

1d agoBenzinga

Boston Scientific (BSX) Faces A Recall, Is The 28% Undervaluation Still Compelling?

2d agoYahoo Finance

Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?

According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

2d agoYahoo Finance

What Do Boston Scientific (BSX) Recall And Executive Retirement Mean For Investors?

Boston Scientific (NYSE: BSX) has started a voluntary global recall of its StoneSmart Connect Console over a power adapter safety issue. The company is informing hospitals and healthcare providers worldwide about the recall and advising on identification and return of affected units. Arthur C. Butcher, who oversees key endoscopy and urology portfolios, has notified Boston Scientific of his decision to retire. The recall of StoneSmart Connect and Arthur C. Butcher's retirement only capture...

2d agoYahoo Finance

Also Discussed

Investors talking about BSX also mention

#	Name	Attention
1	Stryker CorporationSYK	0.01%+0.01
2	Medtronic plcMDT	0%-0.01
3	Edwards Lifesciences CorporationEW	0%new
4	Intuitive Surgical Inc.ISRG	0%0
5	Abbott LaboratoriesABT	0%-0.03
6	Zimmer Biomet Holdings, Inc.ZBH	0%0
7	NVRO - Nevro Corp.	——
8	Becton, Dickinson and CompanyBDX	0%0
9	CSII - Cardiovascular Systems, Inc.	——
10	The Baldwin Insurance Group, Inc. Class A Common StockBWIN	0%new

Boston Scientific Corp.

Healthcare
Medical Devices

Boston Scientific Corp. is a medical device company focused on developing, manufacturing, and marketing technologies used in interventional medical procedures worldwide. The company’s portfolio serves a broad range of clinical areas, including cardiology, peripheral interventions, endoscopy, urology, and neuromodulation. Its MedSurg segment covers products for digestive health, urinary care, and pain management, while its Cardiovascular segment supports minimally invasive treatment options for heart and vascular conditions. Boston Scientific’s devices are designed to help healthcare professionals diagnose and treat patients through less invasive approaches across hospitals, clinics, and specialized medical centers. Headquartered in Marlborough, Massachusetts, Boston Scientific plays a significant role in the global health care equipment market through its broad mix of procedure-based products and physician-focused solutions.

Website

Location

300 Boston Scientific Way

Marlborough, MA, 01752-1234

United States

Social

What share of all stock conversation is about BSX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.03% -0.02	0.02% -0.01	0.05% +0.03	0.01% +0

Sep 29

Boston Scientific / Med Tech has seen guidance cuts that may have contributed to an interesting chart, potentially leading to a secular health technology backwind in the 2050s.
Congressman Kevin Hern has sold up to $6.3 million in stocks, including $BSX, with his sales dwarfing his purchases, including Apple.
A large premium of $2.1 million has been paid for the $BSX 40C Jan 21 option contract, indicating potential large-scale trading activity.

Generated by AI

Sentiment

Of the messages about BSX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	94.34% +66.21	84.85% +21.12	65.85% -27.84	58.13% -37.32
Bearish	5.66% -66.21	15.15% -21.12	34.15% +27.84	41.87% +37.32

Bullish· Sep 10

Boston Scientific's management is actively buying the stock, with Chairman and CEO Michael Mahoney making an enormous open-market purchase of 186,240 shares at an average price of approximately $48.33.
The stock's fair value is likely to be $55-$65, and it may reach this price around April 2027 at the current rate.
Despite concerns about the cybersecurity disruption and slower growth expectations, the stock is undervalued and presents a unique opportunity, with many insiders and experts remaining bullish on its future prospects.

Bearish· Sep 10

The CEO's buy during the cyberattack was seen as poor timing, and the company's momentum was severely impacted.
The stock has been unable to recover from its losses, with the majority of posts indicating a trend of new lows and a lack of turnaround in sight.
The company's fundamental value has been questioned, with one post suggesting that buying fundamentally cheap stocks has been a disaster, and another recommending selling November 20 puts to collect a premium.

Generated by AI

Topics

Of the messages about BSX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	75%	86.05%	1.08%	4.98%
Technical Analysis	25%	13.18%	2.06%	4.77%
Analysts	0%	0%	50.36%	47.19%
Macro	0%	0%	46.42%	38.84%
Controversies	0%	0.78%	0.06%	2.15%
Earnings	0%	0%	0.03%	2.07%

Earnings· Feb 4

Boston Scientific's Q4 2025 earnings reported adjusted EPS of $0.80, beating estimates of $0.78.
Revenue for Q4 2025 was $5.29B, exceeding estimates of $5.28B and marking a 15.9% year-over-year growth.
The company guided Q1 2026 EPS to be between $0.78 and $0.80, and FY26 adjusted EPS to be between $3.43 and $3.49.

Analysts· Jan 1

Boston Scientific Corporation (BSX) is included in J.P Morgan's top stock picks for 2026 with an "overweight" rating and a price target of $135.00.
The analysts at J.P Morgan have expressed optimism about the company's prospects, although specific details of their reasoning are not provided.
The inclusion of BSX in J.P Morgan's top stock picks is seen as a positive development for the company's stock price.

Announcements· Aug 26

Boston Scientific ($BSX) disclosed a cybersecurity incident that disrupted global operations, including systems used to process and ship customer orders.
The incident, detected on August 25, has caused a network outage and prevented the company from processing and shipping customer orders worldwide.
The company has not concluded whether the incident rises to a reportable level, and the financial impact and restoration timeline are unknown.

Technical Analysis· Jun 2

$BSX is down to test 2004 highs and may be due for a bounce.
The weekly chart shows $BSX has arrived at its trend curve, indicating a potential bounce starting soon.
A bullish divergence on the daily chart for CCI and volume against declining share prices suggests a reversal action may be inbound.

Generated by AI

Community

Of the messages about BSX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	3.86%	32.09%	65.27%	42.33%
Newcomers	96.14%	67.91%	34.73%	57.67%

Regulars· Sep 25

The management team is under scrutiny for the stock's performance, with some users calling for a change in leadership and others expressing frustration with the current team's competence.
The stock's price has been stagnant, with some users pointing to a "dirty fucking short ladder pattern" and others referencing a "short ladder" in a negative light, suggesting a lack of upward momentum.
Some users are holding onto hope for a "desperate pump" or a "buy the dip" opportunity, while others have given up and are looking to exit their positions, with one user stating they'll come back in at $38.

Newcomers· Sep 25

Newcomers to $BSX are focusing on the company's potential opportunities in healthcare, with some expressing high conviction in its stock.
Some users are analyzing the company's recent performance, including CEO purchases and buybacks, and are concerned about its support levels and potential for losses.
Others are questioning the stock's volatility, with one user stating that it can easily wipe out all its gains in a single day, and another expressing frustration with retail investors' impatience and lack of understanding of the market.

Generated by AI

Boston Scientific

Social

Sep 29

Bullish· Sep 10

Bearish· Sep 10

Earnings· Feb 4

Analysts· Jan 1

Announcements· Aug 26

Technical Analysis· Jun 2

Regulars· Sep 25

Newcomers· Sep 25

Could Boston Scientific’s $300 Million Cyber Hit Be Mostly a 2026 Problem?

Why Oppenheimer Cut Boston Scientific’s Price Target by $20 Despite Keeping its Outperform Rating

FDA Flags Boston Scientific Catheter Recall - Boston Scientific (NYSE:BSX)

Boston Scientific (BSX) Faces A Recall, Is The 28% Undervaluation Still Compelling?

Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?

What Do Boston Scientific (BSX) Recall And Executive Retirement Mean For Investors?

Also Discussed

Boston Scientific Corp.

Company Information

Location

Could Boston Scientific’s $300 Million Cyber Hit Be Mostly a 2026 Problem?

Why Oppenheimer Cut Boston Scientific’s Price Target by $20 Despite Keeping its Outperform Rating

FDA Flags Boston Scientific Catheter Recall - Boston Scientific (NYSE:BSX)

Boston Scientific (BSX) Faces A Recall, Is The 28% Undervaluation Still Compelling?

Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?

What Do Boston Scientific (BSX) Recall And Executive Retirement Mean For Investors?

Also Discussed

Social

Sep 29

Bullish· Sep 10

Bearish· Sep 10

Earnings· Feb 4

Analysts· Jan 1

Announcements· Aug 26

Technical Analysis· Jun 2

Regulars· Sep 25

Newcomers· Sep 25